Summary: Treatment-Naive Genotype 1a With Compensated Cirrhosis
Recommended regimens listed by evidence level and alphabetically for:
Treatment-Naive Genotype 1a Patients With Compensated Cirrhosisa 
|
|
RECOMMENDED
|
DURATION
|
RATING 
|
|
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASsb for elbasvir
|
12 weeks
|
I, A
|
|
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)
|
12 weeks
|
I, A
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)
|
12 weeks
|
I, A
|
|
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)c
|
8 weeks
|
I, B
|
a For decompensated cirrhosis, please refer to the appropriate section.
b Includes genotype 1a RASs at amino acid position 28, 30, 31, or 93 known to confer antiviral resistance. If 1 or more RASs are present, another recommended regimen should be used.
c Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. For patients with HIV/HCV coinfection, a treatment duration of 12 weeks is recommended.
|
